Pelthos Therapeutics Inc. (PTHS) vs Rallybio Corporation (RLYB)

Pelthos Therapeutics Inc. and Rallybio Corporation are both Biotechnology companies. Pelthos Therapeutics Inc. and Rallybio Corporation are of similar size ($88.2M and $85.8M). Pelthos Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 2.1×. Rallybio Corporation has the higher net margin (0.00% vs −199.5%) and the lower return on invested capital (−1,052.0% vs −82.3%). Across the 15 metrics below, Rallybio Corporation leads on 10 and Pelthos Therapeutics Inc. on 5.

Valuation

Metric PTHS RLYB Biotechnology median
P/E n/m 2.06 7.88
P/S 1.82 110.39 11.47
P/B n/m 1.00 2.52
Price to free cash flow n/m 3.55 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2.92 2.18 10.73
Earnings yield (128.97%) 48.49% (28.84%)
Free cash flow yield (54.04%) 28.17% (23.03%)

Profitability

Metric PTHS RLYB Biotechnology median
Gross margin 78.59% 100.00% 65.16%
Operating margin (133.42%) 0.00% 0.00%
Net margin (199.50%) 0.00% 0.00%
Free cash flow margin (98.37%) 0.00% 0.00%
Return on equity 2,161.07% 64.86% (57.72%)
Return on assets (125.04%) 61.12% (49.22%)
Return on invested capital (82.34%) (1,052.03%) 0.00%

Growth

Metric PTHS RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 5.64%
EPS growth (last fiscal year) (61.12%) 85.06% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric PTHS RLYB Biotechnology median
Debt to equity (46.58) 0.00 0.00
Current ratio 1.98 27.26 4.73
Net debt to EBITDA (0.45) 1.63 0.96

Dividend

Metric PTHS RLYB Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric PTHS RLYB Biotechnology median
Market cap 85.76m 88.21m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack